Lyra Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
OTC.Pink
Lyra Therapeutics hires Alliance Advisors to assist with proxy solicitation for its 2025 Annual Meeting of Stockholders.
OTC.Pink
Lyra Therapeutics' upcoming annual meeting on May 14, 2025, includes proposals for director elections, auditor ratification, and a potential reverse stock split.
OTC.Pink
DEF: Lyra Therapeutics Seeks Stockholder Approval for Reverse Stock Split to Maintain Nasdaq Listing
Lyra Therapeutics is asking stockholders to approve a reverse stock split proposal at its upcoming annual meeting to maintain its Nasdaq listing and potentially facilitate future capital raising.
OTC.Pink
DEFA14A: Lyra Therapeutics Sets Date for 2024 Annual Meeting, Outlines Key Proposals for Stockholder Vote
Lyra Therapeutics announces its 2024 Annual Meeting of Stockholders to be held virtually on June 13, 2024, with voting open until June 12, 2024, covering director elections, auditor ratification, and officer exculpation.
OTC.Pink
Lyra Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on June 13, 2024, to vote on director elections, auditor ratification, and an amendment to the company's Restated Certificate of Incorporation.